๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

SBRT clinical trials

Also listed in trial records as AT1019
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 8 trials in our China and USA registers that name SBRT as an intervention. Synced 25 Sep 2026
8Current trials
6Recruiting now
7Lead sponsors
2Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards
At a glance

SBRT is named as an intervention in 8 current clinical trials in our China and USA registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Zibo Municipal Hospital (2). The most-studied condition is NSCLC.

Trials by status

  • Recruiting675%
  • Not yet open225%

Trials by phase

  • Phase 2788%
  • Phase 1113%
01

Clinical trials of SBRT

8 trials
StudyPhaseStatusLead sponsorRegisters
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
NCT04302025 · Non-small Cell Lung Cancer
Phase 2 Recruiting Genentech, Inc. USA
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
NCT06676722 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
Phase 2 Recruiting The First Affiliated Hospital of Xiamen University China
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage โ…กA-โ…ขB Non-small Cell Lung Cancer
NCT06877299 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell Lung Cancer
Phase 2 Recruiting Sichuan University China
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer๏ผšA Prospective, Single-Arm, Phase II Study
NCT07085182 · ClinicalTrials.gov ↗ · NSCLC, Tislelizumab, Chemotherapy
Phase 2 Recruiting Zibo Municipal Hospital China
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
NCT07198217 · ClinicalTrials.gov ↗ · NSCLC, Tislelizumab, Chemotherapy
Phase 2 Recruiting Zibo Municipal Hospital China
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
NCT07285395 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting The Affiliated Hospital of Xuzhou Medical University China
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
NCT07379398 · ClinicalTrials.gov ↗ · NSCLC
Phase 2 Not yet open Tianjin Medical University Cancer Institute and Hospital China
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
NCT07683221 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Phase 2 Not yet open Shandong Cancer Hospital and Institute China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with SBRT

11 conditions
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Zibo Municipal Hospital2
Genentech, Inc.1
Sichuan University1
The First Affiliated Hospital of Xiamen University1
Tianjin Medical University Cancer Institute and Hospital1
Shandong Cancer Hospital and Institute1
The Affiliated Hospital of Xuzhou Medical University1
04

By country register

RegisterTrialsRecruiting
Clinical trials in China75
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about SBRT trials

How many clinical trials are testing SBRT?

8 current trials in our China and USA registers name SBRT (also registered as AT1019) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are SBRT trials recruiting patients?

Yes. 6 of the 8 trials are recruiting: 5 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors SBRT clinical trials?

Zibo Municipal Hospital (2), Genentech, Inc (1), Sichuan University (1) and The First Affiliated Hospital of Xiamen University (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SBRT works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how SBRT works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SBRT (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.